T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are neoplasms that originate from T-cell precursors. Outcomes in adult patients with T-ALL/LBL remain unsatisfactory; early relapse following intensive induction chemotherapy is a concern, and patients with relapsed or refractory disease have a poor prognosis. Romidepsin is a potent, class 1 selective histone deacetylase inhibitor approved for the treatment of patients with peripheral T-cell lymphoma who have had ≥1 prior therapy and patients with cutaneous T-cell lymphoma who have had ≥1 prior systemic therapy. Here, we report the case of an adult patient with T-ALL refractory to induction hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexa- regimens have been reported, the optimal reinduction therapy for relapsed or refractory T-ALL or T-LBL remains unclear. 5,7,11 Radiation was added for the first progression, and romidepsin was added for
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lymphoma [PTCL] and cutaneous T-cell lymphoma [CTCL]) in the
United States, 13 was chosen because it was unlikely to exacerbate her mucositis due to chemoradiotherapy, to significantly worsen her neutropenia, or add end-organ toxicity. Upon rapid progression after induction with a standard adult induction regimen, the patient consented to salvage therapy with hyper-CVAD with the addition of romidepsin.
| PATIENT DATA AND METHODS
A 38-year-old previously healthy woman presented to an outside hos- therapy and for patients with CTCL who have had ≥1 prior systemic therapy. 13 Although the underlying mechanisms remain unclear, HDAC inhibitors in general, and romidepsin in particular, have demonstrated activity in mature T-cell lymphomas. [17] [18] [19] [20] In the 2 pivotal phase 2 trials that led to approvals in each respective indication (PTCL and CTCL), romidepsin induced durable responses with manageable toxicity. [18] [19] [20] Furthermore, manageable myelosuppression has been reported with romidepsin added to standard cell cycle-active chemotherapy, suggesting that it could be combined with our patient's treatments for primary refractory disease (dose-intense induction chemotherapy and radiation). 21 In the case presented here, one reason for the selection of romidepsin was the potential for minimal toxicity when added to chemotherapy for the primary refractory T-ALL. Romidepsin given to Romidepsin-containing chemotherapy regimens deserve further study in this high-risk population.
